USPTO serial 88221050
NOVOCOL PHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 21, 2024
- Examiner
- FATHY, DOMINIC
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NOVOCOL PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Saint-Maur-des fosses, FR
Saint-Maur-des fosses, FR
Saint-Maur-des fosses, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JASON J. MAZUR
JASON J. MAZUR ARENTFOX SCHIFF LLP1717 K STREET, NWWASHINGTON, DC 20006-5344UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
| 010 | Drug delivery systems, namely, needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
| 035 | Business consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies, method development, formal stability, registration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
| 040 | Contract manufacturing of clinical batches of pharmaceuticals; Consulting services relating to pharmaceutical manufacturing, batch biological treatment batches, and pharmaceutical manufacturing; custom manufacture of pharmaceuticals, namely, the formulation of new dosage forms and the reformulation of existing drug products; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
| 042 | Consulting services relating to the clinical testing, inspection, or research of pharmaceuticals; Consulting services relating to conducting pharmaceutical stability studies and formal stability studies; Consulting services relating to the development of chemical production methods; Consulting services relating to registration batch research and commercial pharmaceutical products development; Pharmaceutical drug development services, namely, the formulation of new dosage forms and the reformulation of existing drug products; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
| 045 | Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; Consulting services relating to pharmaceuticals relating to regulatory compliance in the field of pharmaceuticals, namely, regulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Septodont Holding SAS
- Other trademarks owned by Septodont Holding SAS
- Other trademarks owned by Septodont Holding SAS
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named NOVOCOL PHARMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 21, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 21, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2024 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Apr 16, 2024 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Apr 16, 2024 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Oct 4, 2023 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jun 26, 2023 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 6, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 6, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 17, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 28, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 26, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2023 | ALIE | ASSIGNED TO LIE | — |
| Apr 18, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 20, 2023 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 20, 2023 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 20, 2023 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jan 18, 2023 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 23, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 23, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 23, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 18, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 18, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 17, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Mar 1, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 1, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 1, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 23, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 23, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 23, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 18, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 17, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 17, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 17, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 17, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 17, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 14, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 30, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 30, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 30, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 13, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 2, 2020 | ALIE | ASSIGNED TO LIE | — |
| Feb 28, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 28, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 28, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 3, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 3, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 3, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 30, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 11, 2018 | NWAP | NEW APPLICATION ENTERED | — |